Disordered oesophageal motility in thyrotoxic myopathy

M.C.M. Sweatman* and L. Chambers

Edgware General Hospital, Edgware, Middlesex, HA8 0AD, UK.

Summary: Dysphagia is an uncommon feature of thyrotoxic myopathy, and is usually associated with other signs of bulbar weakness, such as dysarthria and nasal regurgitation. We report a case of thyrotoxicosis presenting with dysphagia due to diminished oesophageal motility associated with significant hypercalcaemia; both abnormalities resolved rapidly following treatment.

Introduction

Chronic thyrotoxic myopathy was initially considered rare (Waldenstrom, 1945; Whitfield & Hudson, 1961), but with the advent of electromyography it has become apparent that myopathy to some extent is virtually ubiquitous among thyrotoxic patients (Havard et al., 1963; Satoyoshi et al., 1963a; Ramsay, 1966). This report describes a rare presentation of thyrotoxic myopathy and reviews briefly bulbar and oesophageal involvement in such patients.

Case report

A 71 year old woman presented with a 3 month history of dysphagia, associated with a sensation of solid food sticking at the lower retrosternal region, and anorexia. There was no history of nasal regurgitation and speech had remained normal; she had lost 14 stones in weight during this time. Three weeks before admission she had fallen, and afterwards noticed progressive muscle weakness, such that she could not rise from a sitting or lying position, climb stairs or lift objects above her head.

She had received iodine therapy for thyrotoxicosis presenting with a goitre at the age of 18 y and further medical treatment for a recurrence of exophthalmos at 38 y.

On admission there was bilateral symmetrical weakness of neck and trunk flexion and profound symmetrical muscle weakness in the upper and lower limbs mainly affecting proximal muscles but with some distal involvement in the upper limbs. There was wasting of the small muscles of the hand. Reflexes were brisk and symmetrical with a left flexor and right equivocal plantar response. Tone, sensation and coordination were normal.

Full blood count, urea, electrolyte, blood sugar and creatine kinase estimations were normal. Serum calcium was elevated to 3.08 mmol/l corrected. Serum phosphate was 1.42 mmol/l and serum albumin 32 g/l. A Tensilon test was equivocal on one occasion and negative when repeated. Barium swallow and meal revealed unequivocally diminished oesophageal peristaltic activity, with no other lesion.

A tentative diagnosis of thyrotoxic myopathy presenting with dysphagia was confirmed by the finding of a serum thyroxine of 258 nmol/l. Auto-antibodies to thyroid microsomal fraction were demonstrated at one in a hundred dilution.

Electromyography revealed a frankly myopathic pattern in all sampled muscles; nerve conduction studies confirmed normal sensory and motor conduction and there was no evidence of neuromuscular blockade.

Following treatment with carbimazole, 15 mg t.d.s., serum calcium rapidly returned to normal and the dysphagia recovered. The proximal myopathy resolved within 6 weeks and the patient has remained well since that time.

Discussion

Bulbar involvement is considered a rare manifestation of thyrotoxicosis (Havard, 1962; Ramsay, 1966; Gaan, 1967; Clements et al., 1981), being found in only 55 (21.1%) of approximately 261 patients with thyrotoxic myopathy reported since 1894. Thirty-six of these patients experienced dysphagia, but 15 had either proven or clinically probable myasthenia gravis. Dysphagia occurred as the only manifestation of bulbar involvement in 12 thyrotoxic patients, though as the sole presenting myopathic feature in only one,
associated with recurrent aspiration pneumonia (Marks et al., 1980). Barium studies in 7 patients showed pharyngeal weakness in 5 (Waldenstrom, 1945; Strong, 1949; Heinrich et al., 1962; Marks et al., 1980), and were normal in 2 (Morgan & Williams, 1940; Gaan, 1967). In one patient with dystrophia myotonica, thyrotoxicosis and dysphagia, manometry revealed marked pharyngeal weakness with absent oesophageal peristalsis, which resolved following carbimazole therapy (Leach, 1962).

Our patient had moderate hypercalcaemia, which was undoubtedly a manifestation of thyrotoxicosis, since the serum calcium was rapidly corrected following treatment. Significant hypercalcaemia and its clinical sequelae are rare in thyrotoxicosis (Hall et al., 1980), and an association with bulbar or oesophageal weakness has never been described.

Loss of oesophageal peristalsis causing dysphagia is an unusual occurrence in thyrotoxic myopathy, and an unlikely chance association, as both resolved rapidly following treatment. The mechanism for this disordered oesophageal motility remains uncertain; Grieve & Dixon (1983) have described 2 patients with metastatic squamous carcinoma of the bronchus and hypercalcaemia; both experienced severe dysphagia without mechanical obstruction, though one had mildly impaired pharyngeal muscular co-ordination. They suggested that hypercalcaemia may cause dysphagia by an effect on neurotransmitter release at the neuromuscular junction, since rapid recovery follows correction of the elevated serum calcium.

In patients with weight loss, dysphagia, myopathy and hypercalcaemia it is important to distinguish between carcinomatous neuromyopathy and thyrotoxicosis, since the latter is readily amenable to treatment, but if left undiagnosed and untreated, could easily lead to recurrent aspiration pneumonia, with its attendant morbidity.

Acknowledgements

We are grateful for the help of Dr Peter P. Turner under whose care the patient was admitted, and to Miss T. Chudleigh and Miss A. Van Loen for secretarial assistance.

References


Disordered oesophageal motility in thyrotoxic myopathy.

M. C. Sweatman and L. Chambers

*Postgrad Med J* 1985 61: 619-620
doi: 10.1136/pgmj.61.717.619

Updated information and services can be found at:
http://pmj.bmj.com/content/61/717/619

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/